Songmao Zheng, Ph.D.
UF Postdoctoral Associate (September 2012 to December 2013)
Currently working as a Senior Scientist at Janssen Biotherapeutics, Janssen R&D.
- Ph.D. Pharmaceutical Sciences, University of Washington (UW), Seattle, WA, 2007-2012
- B.S. Biological Sciences, Sichuan University (SCU), Chengdu, China, 2003-2007
– Honored study abroad at SCU-UW Exchange Program, Seattle, WA, 2005-2006
Dr. Songmao Zheng joined the Center for Pharmacometrics and Systems Pharmacology in the Department of Pharmaceutics, College of Pharmacy, University of Florida at Lake Nona (Orlando) as a postdoctoral associateIn September 2012. His research focused on the use of quantitative data analysis and systems pharmacology tools to address critical clinical research and drug development questions and to support regulatory decision making in the area of protein therapeutics, anti-infectives and orphan drugs. He has co-authored a state-of-the-art review in Clinical Pharmacology & Therapeutics focusing on systems approach in drug risk assessment.
Dr. Zheng received his Ph.D. in Pharmaceutical Sciences from the University of Washingtonin August 2012 under the supervision of Dr. Kenneth E. Thummel. His doctoral thesis was “The Impact of CYP3A5 Variation and Pregnancy on the Metabolic Disposition of Calcineurin Inhibitors”, highlighting clinical studies in which he played a primary role, led by Dr. Thummeland Dr. Mary F. Hebert. For his thesis projects, heco-authored 6 publications, including 4 first-author original research articles that presented analytical method development, enzyme kinetics characterization and quantitative modeling and analysis of clinical data. He received awards including AAPS PPDM, CPTR and Amgen travel award for various projects, including his internship project on PK/PD Modeling of Antibody Drug Conjugates with Dr. Baiteng Zhao at Seattle Genetics.
Before joining UW Pharmaceutics, he graduated from Sichuan University with a B.S. degree in Biological Sciences in 2007, during which he had a one-year honored exchange under the guidance of Dr. C. Anthony Blau at the Department of Hematology, UW. His research focused on erythropoietin and genetically modified erythroid progenitor cells. In 2007, he was awarded as the most recognized “National Triple-A Outstanding Student” by the Ministry of Education of the People’s Republic of China.
Dr. Zheng is highly passionate about learning and contributing to precision medicine and model-based drug development in the biopharmaceutical industry. After the completion of his postdoctoral training, he was hired by Johnson & Johnson as a PK/PD Scientist.
“My exciting and fulfilling postdoctoral training at the Center for Pharmacometrics and Systems Pharmacology at the University of Florida is not possible without the vision and mentorship of Drs. Larry Lesko and Stephan Schmidt, which is phenomenal, inspiring and invaluable. As part of my training, I also want to thank Dr. Ping Zhao for his excellent guidance on my ORISE fellowship at the USFDA. The abundant opportunities to collaborate and discuss in person with internationally renowned experts in various disciplines are tremendously instrumental. The emphasis of the center on cultivating independent and critical thinking as well as interpersonal/leadership skills, together with systematic utilization of appropriate experimental and computational tools to quantitatively address unresolved critical questions in drug disposition/action and in clinical drug development truly sets it apart from other programs. I cannot recommend this program highly enough for those who aim to become future leaders in quantitative pharmacology and personalized medicine.” – Songmao Zheng, Ph.D.
Zheng S, Matzneller P, Zeitlinger M, Schmidt S. Development of population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects. Accepted for publication in Antimicrob Agents Chemother.
Zheng S, Gaitonde P, Andrew MA, Gibbs MA, Lesko LJ, Schmidt S Model-based assessment of dosing strategies in children for monoclonal antibodies exhibiting target-mediated drug disposition. Accepted fo publication in CPT Pharmacometrics Syst Pharmacol.
Lesko LJ, Zheng S, and Schmidt S (2013) Systems Approach in Risk Assessment. Accepted for publication in Clinical Pharmacology & Therapeutics.
Zheng S, Easterling TR, Hays K, Umans JG, Miodovnik M, Clark S, Calamia JC, Thummel KE, Shen DD, Davis CL, andHebert MF (2013) Tacrolimus Placental Transfer at Delivery and Neonatal Exposure through Breast Milk. Accepted for publication in British Journal of Clinical Pharmacology.
Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, and Thummel KE (2013) CYP3A5Gene Variation Influences Cyclosporine A Metabolite Formation and Renal Cyclosporine Disposition.Transplantation.
Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, and Thummel KE (2012)Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenaltacrolimus disposition. Clinical Pharmacology & Therapeutics.
Zheng S, Easterling TR, Umans JG, Miodovnik M, Calamia JC, Thummel KE, Shen DD, Davis CL, and Hebert MF(2012) Pharmacokinetics of tacrolimus during pregnancy. Therapeutic Drug Monitoring.
Hebert MF, Zheng S, Hays K, Shen DD, Davis CL, Umans JG, Miodovnik M, Thummel KE, and Easterling TR (2012)Interpreting Tacrolimus Concentrations During Pregnancy and Postpartum. Transplantation.
Wang Z, Senn T, Kalhorn T, Zheng XE, Zheng S, Davis CL, Hebert MF, Lin YS, and Thummel KE (2011) Simultaneousmeasurement of plasma vitamin D(3) metabolites, including 4beta,25-dihydroxyvitamin D(3), using liquidchromatography-tandem mass spectrometry. Analytical Biochemistry.
Zheng S, Zeitlinger M, Lesko LJ, and Schmidt S “Development of a Semi-mechanistic Tissue Distribution Population Pharmacokinetic Model for Azithromycin”, 26th Annual Research Showcase, College of Pharmacy, University of Florida, 2013
Zheng S &Hebert MFet al.“Pharmacokinetics of Tacrolimus during Pregnancy”, AAPS Annual Meeting，2012 (CPTR travel award)
Zheng S & Thummel KE et al. “The Effect of CYP3A5 Gene Variation on Tacrolimus Metabolite Formation in Vivo”，AAPS Annual Meeting，2011 (PPDM travel award)
Zhao B, Zheng S, and Alley SC “Physiologically-Based Pharmacokinetic Modeling of an Anti-CD70 Auristatin Antibody-Drug Conjugate in Tumor Bearing Mice”, ACoP Conference, 2011
Zhao B, Zheng S, Law CL, and Alley SC “Pharmacokinetic-pharmacodynamic Modeling for Assessment of the Tumor Growth Inhibitory Effect of SGN-75, an Anti-CD70 Antibody Drug Conjugate, in Human Tumor Xenograft Models in Mice”, AAPS National Biotechnology Conference, 2011 (Amgen travel award)
Zheng S & Thummel KE et al. “CYP3A5 genetic polymorphism and the metabolism of Cyclosporine A in healthy volunteers”, Gordon Research Conference (Drug Metabolism), 2010
Miller CP, Zheng S, and Blau CA “Epo-Independent Proliferation and Differentiation of Genetically Modified Erythroid Progenitor Cells Using a Chemical Inducer of Dimerization”, American Society of Hematology 48th Annual Meeting, 2006
Zheng S“Smoking Cessation in Pregnant Smokers”, 8th Annual IHDCYH Summer Institute in Maternal-Fetal and Pediatric Pharmacology, 2012 (Toronto, Ontario)
Zhao B, Zheng S, and Alley SC “Pharmacokinetic-pharmacodynamic Modeling for Assessment of the Tumor Growth Inhibitory Effect of SGN-75, an Anti-CD70 Antibody Drug Conjugate, in Human Tumor Xenograft Models in Mice”, Seattle Genetics Annual Science Day, 2011
Zhao B, Zheng S, Law C-L, and Alley SC “Physiologically-Based Pharmacokinetic Modeling of an Anti-CD70 Auristatin Antibody-Drug Conjugate in Tumor Bearing Mice”, Seattle Genetics Annual Science Day, 2011 (presented by Zhao B)